Kymera Therapeutics Files 8-K

TL;DR

Kymera dropped an 8-K on 12/8/25 - check it for Reg FD, other events, and financials.

AI Summary

Kymera Therapeutics, Inc. filed an 8-K on December 8, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, incorporated in Delaware, is based in Watertown, Massachusetts.

Why It Matters

This 8-K filing provides an update on Kymera Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on standard corporate events and disclosures, not indicating any immediate significant risks.

Key Numbers

• 001-39460 — SEC File Number (Identifies the company's filing history with the SEC.)
• 81-2992166 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Kymera Therapeutics, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Watertown, Massachusetts (location) — Principal executive offices
• December 8, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share KYMR The Nasdaq

Filing Documents

• d69739d8k.htm (8-K) — 47KB
• d69739dex991.htm (EX-99.1) — 33KB
• g69739dsp1.jpg (GRAPHIC) — 8KB
• 0001193125-25-310572.txt ( ) — 219KB
• kymr-20251208.xsd (EX-101.SCH) — 3KB
• kymr-20251208_lab.xml (EX-101.LAB) — 18KB
• kymr-20251208_pre.xml (EX-101.PRE) — 11KB
• d69739d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Kymera Therapeutics, Inc. 500 North Beacon Street , 4th Floor Watertown , Massachusetts 02472 (Address of principal executive offices, including zip code) (857) 285-5300 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trade Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share KYMR The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item7.01 Regulation FD Disclosure. On December 8, 2025, Kymera Therapeutics, Inc. (the "Company") issued a press release, a copy of which is furnished herewith as Exhibit 99.1. On December 8, 2025, the Company will host a video conference call at 8:00 am eastern time to discuss the results from the Company's BroADen Phase 1b atopic dermatitis ("AD") patient trial of KT-621, its first-in-class, oral STAT6 degrader medicine. A replay of the webcast will be available following the event in the "News and Events" section of the "Investors" section of the Company's website at www.kymeratx.com. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing. Item8.01 Other Events On December 8, 2025, the Company announced the results from the Company's BroADen Phase 1b AD patient clinical trial of KT-621, its first-in-class, oral STAT6 degrader medicine. Study Design The KT-621 BroADen Phase 1b trial was an open-label, single-arm study that enrolled 22 patients with moderate to severe AD across two dose levels (enrolled in two sequential cohorts) selected based on results from the KT-621 Phase 1a healthy volunteer study. Ten participants received 100 mg and twelve participants received 200 mg of KT-621 once daily for 28 days, followed by a 14-day follow-up period. Key objectives of the study were to evaluate KT-621 safety and tolerability and to demonstrate that KT-621 could achieve robust STAT6 degradation in both blood and skin, resulting in dupilumab-like reductions in multiple Type 2 inflammatory biomarkers in circulation and in the transcriptome of active AD lesions after 4-weeks of dosing. The study also explored effects on clinical activity and disease burden endpoints. Baseline Characteristics The two dose groups were generally well-balanced for gender, age, race, and measures of disease severity including vIGA-AD, EASI and peak pruritus NRS. The mean baseline EASI score across the two groups was approximately 25. Approximately 46% of patients had comorbid asthma or allergic rhinitis and approximately 23% had prior biologics treatment with either dupilumab and/or tralokinumab. Pharmacokinetics ("PK") and STAT6 Degradation KT-621 exhibited a plasma PK profile across the 100 mg and 200 mg dose groups consistent with the Phase 1a healthy volunteer trial results. KT-621 demonstrated deep and consistent STAT6 degradation in both blood and skin across the 100 mg and 200 mg dose groups, translating strongly from the Phase 1a healthy volunteer study. At Day 29, median STAT6 degradation in bloo

View Full Filing

View this 8-K filing on SEC EDGAR